Abstracts tagged "SLE"

Abstract Number: 1801 • 2015 ACR/ARHP Annual Meeting
Hydroxychloroquine Retinopathy: Application of the 2011 Screening Guidelines in an Academic Practice
Syed Mahmood Shah, Michelle Petri and Hendrik Scholl, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The risk of end-stage retinopathy (bull’s eye maculopathy) from hydroxychloroquine (HCQ) is low (0.65%, Wolfe and Marmor, 2010). With recent advances in retinal structure…
Abstract Number: 2071 • 2015 ACR/ARHP Annual Meeting
Urinary Osteoprotegerin As Biomarker of Lupus Nephritis Disease Activity: Cross Sectional and Longitudinal Study
Ranjan Gupta¹, Amita Aggarwal², Sudhir sinha³, Liza Rajasekhar⁴, Akhilesh Yadav¹, Priyanka Gaur¹, Ramnath Misra² and Virsingh Negi⁵, ¹Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Department of Biochemistry, CSIR-central drug research institute, Lucknow, India, ⁴Department of Rheumatology, Nizam Institute of Medical Sciences, Hyderabad, India, ⁵Department of Clinical Immunology, JIPMER, Puducherry, India
Background/Purpose: Urinary biomarkers may help in identification, treatment and assessment of response to therapy in patients with lupus nephritis (LN). Osteoprotegerin (OPG) is produced by…
Abstract Number: 3083 • 2015 ACR/ARHP Annual Meeting
Antibody Array Based Proteomic Screening of 274 Serum Markers in Systemic Lupus Erythematosus
Tianfu Wu¹, Huihua Ding², Cristina Arriens³, Chungwen Wei⁴, Jennifer H. Anolik⁵, David R. Karp³, Nancy J. Olsen⁶, Michelle Petri⁷, Ignacio Sanz⁴, Ramesh Saxena⁸ and Chandra Mohan², ¹Department of Biomedical Engineering, University of Houston, Houston, TX, ²Biomedical Engineering, University of Houston, Houston, TX, ³Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Rheumatology, Emory University, Atlanta, GA, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Divsion of Rheumatology, Department of Medicine, Penn State MS Hershey Medical Center, Hershey, PA, ⁷Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ⁸Nephrology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Given that early detection of renal involvement in systemic lupus erythematosus (SLE) and prompt management of the disease can have a significant impact on…
Abstract Number: 88 • 2015 ACR/ARHP Annual Meeting
Integrating Evidence for Genetic Association and Natural Selection Helps Detect New Systemic Lupus Erythematosus Risk Loci in African-Americans
Paula S. Ramos¹, Satria Sajuthi², Jasmin Divers³, Kenneth M. Kaufman⁴, Uma Nayak⁵, Wei-Min Chen⁵, Kelly J. Hunt⁶, Diane L. Kamen⁷, Gary S. Gilkeson⁸, Jyotika K. Fernandes⁷, Ida J. Spruill⁹, Robert P. Kimberly¹⁰, John B. Harley¹¹, W. Timothy Garvey¹², Michèle M. Sale¹³ and Carl D. Langefeld², ¹Department of Medicine, Medical University of South Carolina, Charleston, SC, ²Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ³Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁴Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Public Health Sciences, University of Virginia, Charlottesville, VA, ⁶Public Health Sciences, Medical University of South Carolina, Charleston, SC, ⁷Medicine, Medical University of South Carolina, Charleston, SC, ⁸Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁹Nursing, Medical University of South Carolina, Charleston, SC, ¹⁰Medicine, Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹¹Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹²Department of Nutrition Sciences and Birmingham VA Medical Center, University of Alabama at Birmingham, Birmingham, AL, ¹³Department of Medicine and Center for Public Health Genomics, University of Virginia, Charlottesville, VA
Background/Purpose: In many rheumatologic and autoimmune diseases African Americans (AA) have a higher prevalence and greater disease severity than other ethnicities. We posit that population-specific…
Abstract Number: 758 • 2015 ACR/ARHP Annual Meeting
Dominican Patients with Systemic Lupus Erythematosus Residing in New York City Have a Higher SLICC/ACR Damage Index Than Those in the Dominican Republic
Laura Geraldino-Pardilla¹, Ivonne Canto², Thania Perez³, Jossiell Then², Esthela Loyo⁴ and Anca D. Askanase⁵, ¹Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Rheumatology, Hospital Regional Universitario Jose Maria Cabral y Baez, Santiago, Dominican Republic, ³Columbia University, College of Physicians & Surgeons, New York, NY, ⁴Rheumatology, Hospital Regional Universitario, Santiago, Dominican Republic, ⁵Department of Medicine Rhemuatology, Colombia University, New York, NY
Background/Purpose: Higher accrual of damage has been reported in Hispanics with systemic lupus erythematosus (SLE) in the United States. This study was initiated to evaluate…
Abstract Number: 1072 • 2015 ACR/ARHP Annual Meeting
Baseline Gene Expression Profiles in 1760 Patients from Two Phase III Trials of BAFF/BLyS Blockade in SLE
Robert W Hoffman¹, Joan T Merrill², Marta E. Marta Alarcón Riquelme³, Michelle Petri⁴, Ernst R Dow⁵, Eric Nantz⁶, Laura K Nisenbaum⁵, Krista M Schroeder⁶, Wendy J Komocsar⁶, Narayanan B Perumal⁵, Matthew D Linnik⁶, Guilherme V Rocha⁶ and Richard E Higgs⁶, ¹Immunology-Medical, Eli Lilly and Company, Indianapolis, IN, ²OMRF, Oklahoma, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Johns Hopkins Lupus Center, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Eli Lilly and Company, Indiananpolis, IN, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Elevated Type-I interferon (IFN) signature characterizes at least 50% of adults with SLE and has been associated with autoantibodies and more severe disease in…
Abstract Number: 1811 • 2015 ACR/ARHP Annual Meeting
Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus
April Jorge¹, Apinya Lertratanakul², Julia (Jungwha) Lee³, William Pearce¹, David McPherson⁴, Trina Thompson⁵, Emma Barinas-Mitchell⁶ and Rosalind Ramsey-Goldman¹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Chicago, IL, ³Department of Preventive Medicine, Biostatistics Collaboration Center, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴University of Texas Health Science Center, Houston, TX, ⁵Saint Francis University, Ebensburg, PA, ⁶University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Women with SLE have an increased incidence of premature cardiovascular disease (CVD). Depression is also common among SLE patients. A relationship between depression and…
Abstract Number: 2081 • 2015 ACR/ARHP Annual Meeting
The SLE Workshop: An Evaluation of a Long-Standing Hospital-Based Psychoeducational Program
Melissa T. Flores¹, Roberta Horton¹, Jillian A. Rose¹, Stephen A. Paget² and Michael Lockshin³, ¹Social Work Programs, Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York, NY, ³Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY
Background/Purpose: An evaluation was conducted of a monthly hospital-based psychoeducational support group, ongoing since 1985, for people with lupus. Each 2-hour session begins with a…
Abstract Number: 3085 • 2015 ACR/ARHP Annual Meeting
Platelet Activation and Endothelial Reactivity in the Pathogenesis of Tissue Inflammation/Injury in Systemic Lupus Erythematosus
Robert Clancy¹, Sokha Nhek², Jonathan Newman³, Janet Nwaukoni¹, Sara Rasmussen⁴, Jill P. Buyon¹, Maya Rubin⁵, Kristen Lee¹ and Jeffrey Berger⁵, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵Medicine, Division of Cardiology, New York University School of Medicine, New York, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for widespread endothelial dysfunction, vascular thromboses, and premature cardiovascular disease. Enhanced platelet activation and…
Abstract Number: 94 • 2015 ACR/ARHP Annual Meeting
NGS Panel for the Detection of Monogenic SLE in Children: Initial Results
Alexandre Belot¹, Gillian Rice², Anne-Laure Mathieu¹, Brigitte Bader-Meunier³, Thierry Walzer¹, Tracy A. Briggs², James O'Sullivan⁴, Simon Wiliams⁵, Michael W. Beresford⁶, Yanick Crow^2,7 and GENIAL Investigators, UK JSLE Study Group, ¹INSERM U1111, Lyon, France, ²Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ³Pediatric Rheumatology & Immunology, Necker hospital, Imagine Institution, Paris, France, ⁴University of Manchester, Manchester, United Kingdom, ⁵University of Manchester, Manchester, France, ⁶Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁷Neuroinflammation, Institut Imagine, Paris, France
Background/Purpose: Next generation sequencing (NGS) represents a revolution in the field of molecular medicine, and offers a new approach to deciphering the pathogenesis of complex…
Abstract Number: 772 • 2015 ACR/ARHP Annual Meeting
Post-Phlebotomy Stability of Soluble and Cellular Forms of Complement Activation: Implications in SLE Diagnostic Assays
John Conklin¹, Basil Jones², Tyler O'Malley³, Duncan Poling⁴, JoAnne Ligayon⁵, Leilani Wolover⁶, Ying Qu⁷, Claudia Ibarra⁸, Puja Chitkara⁹ and Thierry Dervieux³, ¹1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ²Exagen Diagnostics, Vista, CA, ³Research and Development, Exagen Diagnostics, Vista, CA, ⁴Research and Development, Exagen Diagnostics Inc., Vista, CA, ⁵Flow Cytometry, Exagen Diagnostics Inc., Vista, CA, ⁶Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁷Exagen Diagnostic Inc, Vista, CA, ⁸Clinical Laboratory, Exagen Diagnostics, Vista, CA, ⁹Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA
Background/Purpose: Deregulation and activation of the classical complement system is known to be associated with systemic lupus erythematosus (SLE). As such, several investigators have proposed…
Abstract Number: 1074 • 2015 ACR/ARHP Annual Meeting
DNA Methylation Patterns in Naïve CD4+ T Cells Identify Epigenetic Susceptibility Loci for Malar Rash and Discoid Rash in Systemic Lupus Erythematosus
Paul Renauer¹, Patrick Coit¹, Matlock A. Jeffries², Joan T. Merrill³, W Joseph McCune⁴, Kathleen Maksimowicz-McKinnon⁵ and Amr H. Sawalha⁶, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ⁵Rheumatology, Henry Ford Hospital, Detroit, MI, ⁶Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by heterogeneous clinical manifestations, autoantibody production, and epigenetic dysregulation in T cells. We sought…
Abstract Number: 1813 • 2015 ACR/ARHP Annual Meeting
Novel Mechanism of Action of Anti-Malarial Drugs in the Inhibition of Type I Interferon Production
Jie An¹, Joshua Woodward², Mark Minie³, YuFeng Peng⁴, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, Department of Medicine & Immunology, University of Washington, Seattle, WA, ²Department of Microbiology, University of Washington, Seattle, WA, ³Department of Bioengineering, University of Washington, Seattle, WA, ⁴Rheumatology, University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶Department of Medicine & Immunology, University of Washington, Seattle, WA
Background/Purpose: Anti-malarial drugs (AMD) such as Hydroxychloroquine (HCQ) and Quinacrine (QC) are effective in the treatment of skin rash and arthritis in systemic lupus erythematosus…
Abstract Number: 2125 • 2015 ACR/ARHP Annual Meeting
Rheumatic and Non-Rheumatic Autoimmune Diseases in SLE Offspring
Julie Couture¹, Sasha Bernatsky², Susan Scott³, Christian A. Pineau² and Evelyne Vinet², ¹McGill University Health Centre, Montreal, QC, Canada, ²Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ³Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Autoimmune diseases (AID) have familial aggregation and frequently share a common genetic predisposition. Only few small uncontrolled studies have evaluated the risk of AID…
Abstract Number: 3127 • 2015 ACR/ARHP Annual Meeting
Serologic Diagnosis of Human Neuropsychiatric Lupus Using the Immunarray ICHIP®
Chaim Putterman¹, D. Scott Batty², I.R. Cohen³, Nicole Jordan⁴, Debbie Rybak¹, Tamar Rubinstein¹, Keren Jakobi⁵, Rachel Sorek⁵, Anat Reiner-Benaim⁵, Yakov Blumenstein⁵ and Pennina Safer⁵, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²ImmunArray Inc., Richmond, VA, ³Weizmann Institute of Science, Rehovot, Israel, ⁴Montefiore Medical Center, New York, NY, ⁵ImmunArray LTD, Rehovot, Israel
Background/Purpose: Peripheral neurologic syndromes and central nervous system (CNS) manifestations are recognized as primary disease manifestations in systemic lupus erythematosus (SLE). Neuropsychiatric SLE (NPSLE) involves…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].